Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Richard Warren, J.m. Carrascosa, E. Fumero, A. Schoenenberger, M.g. Lebwohl, J.c. Szepietowski, K. Reich

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial'. Together they form a unique fingerprint.

Medicine and Dentistry